Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Metitepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 6/20 | 0.85 |
| ▸ | DRD2 known ✓ | P14416 | 11/20 | 0.61 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | HTR7 | P34969 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | RAD52 | P43351 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metitepine SCHEMBL31360614 | 1.00 | MAPT (1.00) | MAPTHTR7TP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL7517783 | 0.92 | HTR7 (1.00) | MAPTHTR7TP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL113526 | 0.92 | HTR7 (1.00) | MAPTHTR7TP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL14359602 | 0.92 | HTR7 (1.00) | MAPTHTR7TP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL29496251 | 0.92 | HTR7 (1.00) | MAPTHTR7TP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL15475310 | 0.88 | MAPT (1.00) | MAPTHTR7TP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL2048660 | 0.88 | MAPT (1.00) | MAPTHTR7TP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL8169076 | 0.87 | HTR7 (0.89) | MAPTHTR7TP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL15822282 | 0.82 | MAPT (0.68) | MAPTHTR7TP53CYP3A4SMN1; SMN2 | |
| SCHEMBL11846588 | 0.82 | MAPT (0.75) | MAPTHTR7TP53CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| US-20250352540-A1 | USES OF A PURE 5-HT6 RECEPTOR ANTAGONIST | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-11-20 | — | — | US | disclosed |
| EP-4069231-B1 | COMBINATIONS OF MASUPIRDINE WITH DONEPEZIL OR MEMANTINE FOR TREATING BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH DEMENTIA | SUVEN LIFE SCIENCES LTD (IN) | 2025-07-09 | — | — | EP | disclosed |
| CN-119219598-A | Cyclohexane derivative and medical application thereof | 上海京新生物医药有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119219599-A | Preparation method and intermediate of trans-4- (2- (4- (benzo [ b ] thiophene-7-yl) piperazine-1-yl) ethyl) cyclohexyl) urea | 上海京新生物医药有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-114761008-B | Method for treating behavioral and psychological symptoms in patients suffering from dementia | 苏文生命科学有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | disclosed |
| WO-2004048328-A2 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004000845-A1 | ARYLALKYL INDOLES HAVING SERTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000849-A2 | TETRACYCLIC ARYLSULFONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LIMITED (IN) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000205-A2 | NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2003-12-31 | — | — | WO | disclosed |
| US-20020127544-A1 | Modulators of US 28 | CHEMOCENTRYX | 2002-09-12 | — | — | US | disclosed |
| WO-2002017900-A2 | MODULATORS OF US28 (CHEMOKINES) FOR TREATING CYTOMEGALOVIRUS INFECTIONS | CHEMOCENTRYX, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-0467365-A2 | Use of a 5-hydroxytryptamine-3(5-HT3) receptor antagonist for the preparation of a pharmaceutical composition for treating urinary incontinence | E.R. SQUIBB & SONS, INC. (US) | 1992-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020127544-A1 | Modulators of US 28 | CCR8, CCL5, CXCL10 | HTR1A 3763/4885HTR2A 3814/4885HTR2C 3683/4885 |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | OPRM1, OPRL1, OPRK1 | HTR1A 66/4885HTR2A 56/4885HTR2C 70/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | HTR1A 3/4885HTR2A 1/4885HTR2C 2/4885 |
| US-20250352540-A1 | USES OF A PURE 5-HT6 RECEPTOR ANTAGONIST | HTR6, HTR1A, HTR4 | HTR1A 2/4885HTR2A 9/4885HTR2C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.